

17 November 2023

ASX Announcement

Results of Annual General Meeting

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) advises it held its Annual General Meeting today, at 3.00pm (AEDT).

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange with all resolutions being passed on a poll.

Resolution 4 (Approval of 7.1A Mandate) and Resolution 5 (Renewal of Proportional Takeover Provisions) were passed by a sufficient majority as special resolutions.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick Pharma

Firebrick is a pharmaceutical company founded in 2012 with the mission to develop and commercialise a povidone-iodine nasal spray (www.firebrickpharma.com). The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the US, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

Media enquiries:

Heidi Cuthbert +61 411 272 366 heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com



Disclosure of Proxy Votes

Firebrick Pharma Limited Annual General Meeting Friday, 17 November 2023



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes			Poll Results (if applicable)			Results	
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ADOPTION OF REMUNERATION REPORT	Р	8,612,143	5,106,682 59.30%	1,013,365 11.77%	64,872	2,492,096 28.94%	7,613,778 89.29%	913,016 10.71%	64,872	-
2 RE-ELECTION OF DIRECTOR – PHYLLIS GARDNER	Ρ	70,383,959	66,814,800 94.93%	786,732 1.12%	6,000	2,782,427 3.95%	69,511,878 98.88%	786,732 1.12%	6,000	Passed
3 APPROVAL OF EMPLOYEE INCENTIVE PLAN	Ρ	7,279,822	3,055,226 41.97%	1,272,207 17.48%	17,193	2,952,389 40.56%	5,922,266 82.32%	1,272,207 17.68%	17,193	Passed
4 APPROVAL OF 7.1A MANDATE	Р	70,362,876	66,287,851 94.21%	1,244,184 1.77%	27,083	2,830,841 4.02%	69,033,343 98.23%	1,244,184 1.77%	27,083	Passed
5 RENEWAL OF PROPORTIONAL TAKEOVER PROVISIONS	Р	70,347,613	66,425,952 94.43%	1,188,320 1.69%	42,346	2,733,341 3.89%	69,073,944 98.31%	1,188,320 1.69%	42,346	Passed

